Frontline Key Executives
This section highlights Frontline's key executives, including their titles and compensation details.
Find Contacts at Frontline
(Showing 0 of )
Frontline Earnings
This section highlights Frontline's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-28 | $0.20 | $0.20 |
| Read Transcript | Q3 | 2024 | 2024-11-27 | $0.43 | $0.34 |
| Read Transcript | Q2 | 2024 | 2024-08-30 | $0.67 | $0.62 |
| Read Transcript | Q1 | 2024 | 2024-05-31 | N/A | N/A |
| Read Transcript | Q4 | 2023 | 2024-02-29 | $0.46 | $0.46 |
| Read Transcript | Q3 | 2023 | 2023-11-30 | $0.45 | $0.36 |
| Read Transcript | Q2 | 2023 | 2023-08-24 | $0.83 | $0.94 |
| Read Transcript | Q1 | 2023 | 2023-05-31 | $0.97 | $0.87 |
Frontline Ltd., a shipping company, engages in the seaborne transportation of crude oil and oil products worldwide. It owns and operates oil and product tankers. As of December 31, 2021, the company operated a fleet of 70 vessels. It is also involved in the charter, purchase, and sale of vessels. The company was founded in 1985 and is based in Hamilton, Bermuda.
$16.10
Stock Price
$3.58B
Market Cap
88
Employees
Hamilton, None
Location
Financial Statements
Access annual & quarterly financial statements for Frontline, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $2.05B | $1.80B | $1.43B | $749.38M | $1.22B |
| Cost of Revenue | $1.01B | $1.03B | $949.21M | $718.77M | $684.49M |
| Gross Profit | $1.04B | $776.11M | $481.00M | $30.61M | $536.70M |
| Gross Profit Ratio | 50.95% | 43.07% | 33.63% | 4.10% | 43.95% |
| Research and Development Expenses | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $36.09M | $53.53M | $48.30M | $27.89M | $58.81M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $36.09M | $53.53M | $48.30M | $27.89M | $58.81M |
| Other Expenses | $226.91M | $-24.08M | $-9.48M | $-5.89M | $-29.90M |
| Operating Expenses | $263.00M | $29.45M | $38.82M | $22.00M | $28.90M |
| Cost and Expenses | $1.27B | $1.06B | $988.03M | $740.77M | $713.39M |
| Interest Income | $- | $15.95M | $1.46M | $119.00K | $705.00K |
| Interest Expense | $- | $178.50M | $98.71M | $61.44M | $72.16M |
| Depreciation and Amortization | $339.03M | $230.94M | $165.17M | $165.21M | $138.77M |
| EBITDA | $1.01B | $1.06B | $725.83M | $217.24M | $628.35M |
| EBITDA Ratio | 49.19% | 59.00% | 43.07% | 24.40% | 53.11% |
| Operating Income | $781.71M | $746.67M | $442.80M | $29.85M | $507.80M |
| Operating Income Ratio | 38.13% | 41.43% | 30.96% | 3.98% | 41.58% |
| Total Other Income Expenses Net | $-278.46M | $-90.05M | $16.09M | $-18.08M | $-94.80M |
| Income Before Tax | $503.25M | $656.62M | $473.13M | $-6.51M | $412.99M |
| Income Before Tax Ratio | 24.54% | 36.43% | 33.08% | -0.87% | 33.82% |
| Income Tax Expense | $7.67M | $205.00K | $412.00K | $4.63M | $-14.00K |
| Net Income | $495.58M | $656.41M | $475.54M | $-11.15M | $412.88M |
| Net Income Ratio | 24.17% | 36.42% | 33.25% | -1.49% | 33.81% |
| EPS | $2.23 | $2.95 | $2.22 | $-0.06 | $2.11 |
| EPS Diluted | $2.23 | $2.95 | $2.22 | $-0.06 | $2.09 |
| Weighted Average Shares Outstanding | 222.62M | 222.62M | 214.01M | 198.97M | 195.64M |
| Weighted Average Shares Outstanding Diluted | 222.62M | 222.62M | 214.01M | 198.97M | 197.81M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $425.64M | $490.32M | $556.03M | $578.40M | $415.00M | $377.08M | $512.76M | $497.33M | $530.14M | $382.19M | $300.44M | $217.44M | $213.55M | $171.82M | $170.02M | $193.99M | $174.87M | $247.41M | $387.08M | $411.82M |
| Cost of Revenue | $228.92M | $338.59M | $339.03M | $355.03M | $263.07M | $247.44M | $257.48M | $258.09M | $265.81M | $259.88M | $228.77M | $194.74M | $193.48M | $185.88M | $175.32M | $164.11M | $163.36M | $160.86M | $161.66M | $198.61M |
| Gross Profit | $196.73M | $151.73M | $217.00M | $223.37M | $151.94M | $129.65M | $255.28M | $239.24M | $264.33M | $122.30M | $71.67M | $22.70M | $20.07M | $-14.05M | $-5.30M | $29.89M | $11.52M | $86.55M | $225.42M | $213.21M |
| Gross Profit Ratio | 46.22% | 30.95% | 39.00% | 38.60% | 36.60% | 34.40% | 49.80% | 48.10% | 49.90% | 32.00% | 23.90% | 10.40% | 9.40% | -8.20% | -3.10% | 15.40% | 6.59% | 34.98% | 58.24% | 51.77% |
| Research and Development Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $1.71M | $6.96M | $12.57M | $14.85M | $13.89M | $15.30M | $11.70M | $12.64M | $18.39M | $13.67M | $9.10M | $7.14M | $7.11M | $6.45M | $7.95M | $6.38M | $15.65M | $14.28M | $12.78M | $16.09M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $2.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $1.71M | $6.96M | $12.57M | $14.85M | $13.89M | $15.30M | $11.70M | $12.64M | $18.39M | $13.67M | $9.10M | $7.14M | $7.11M | $6.45M | $7.95M | $6.38M | $15.65M | $14.28M | $12.78M | $16.09M |
| Other Expenses | $65.30M | $-45.00K | $-51.49M | $- | $- | $- | $- | $-14.29M | $-451.00K | $-1.94M | $-264.00K | $970.00K | $-4.48M | $984.00K | $1.31M | $690.00K | $-19.00K | $-1.39M | $368.00K | $537.00K |
| Operating Expenses | $67.01M | $6.92M | $-38.92M | $14.85M | $13.89M | $14.90M | $2.31M | $-1.65M | $17.94M | $11.72M | $8.83M | $7.14M | $2.62M | $6.17M | $7.35M | $5.85M | $8.65M | $14.22M | $12.63M | $15.97M |
| Cost and Expenses | $295.93M | $345.51M | $300.11M | $369.87M | $276.96M | $262.33M | $259.79M | $256.44M | $283.75M | $271.61M | $237.61M | $201.88M | $196.10M | $192.05M | $182.67M | $169.95M | $172.01M | $175.08M | $174.29M | $214.59M |
| Interest Income | $- | $5.05M | $5.33M | $2.23M | $5.37M | $3.80M | $4.86M | $2.87M | $1.08M | $198.00K | $141.00K | $47.00K | $10.00K | $26.00K | $38.00K | $45.00K | $50.00K | $58.00K | $117.00K | $480.00K |
| Interest Expense | $- | $82.44M | $73.38M | $71.38M | $48.06M | $38.11M | $32.39M | $45.42M | $35.86M | $26.96M | $18.93M | $16.97M | $16.80M | $15.22M | $14.65M | $14.76M | $15.20M | $16.10M | $18.23M | $22.63M |
| Depreciation and Amortization | $83.15M | $84.16M | $83.71M | $88.01M | $60.02M | $58.28M | $57.10M | $55.55M | $49.46M | $39.23M | $37.51M | $38.97M | $38.59M | $37.45M | $36.20M | $35.53M | $36.11M | $37.28M | $35.33M | $34.27M |
| EBITDA | $195.02M | $231.85M | $348.34M | $296.54M | $233.92M | $205.83M | $300.72M | $282.15M | $290.96M | $220.83M | $103.56M | $87.08M | $79.83M | $19.48M | $24.20M | $79.11M | $43.80M | $106.90M | $254.97M | $222.25M |
| EBITDA Ratio | 45.82% | 47.29% | 62.65% | 51.27% | 47.73% | 42.00% | 61.65% | 60.93% | 54.88% | 40.95% | 35.52% | 7.58% | 35.76% | 11.26% | 14.90% | 31.85% | 22.18% | 43.21% | 63.54% | 48.44% |
| Operating Income | $129.72M | $144.81M | $255.92M | $208.53M | $138.05M | $114.75M | $252.97M | $240.89M | $246.39M | $110.58M | $62.90M | $-22.49M | $36.31M | $-19.24M | $-11.69M | $24.70M | $2.86M | $70.96M | $225.53M | $208.45M |
| Operating Income Ratio | 30.48% | 29.53% | 46.03% | 36.05% | 33.26% | 30.43% | 49.34% | 48.44% | 46.48% | 28.93% | 20.94% | -10.34% | 17.00% | -11.20% | -6.87% | 12.73% | 1.64% | 28.68% | 58.26% | 50.62% |
| Total Other Income Expenses Net | $-63.20M | $-79.56M | $-66.80M | $-68.90M | $-19.45M | $-7.00M | $-22.14M | $-41.45M | $-6.15M | $42.26M | $-15.79M | $8.21M | $2.20M | $-13.95M | $-14.97M | $4.18M | $-11.99M | $-13.85M | $-25.85M | $-43.11M |
| Income Before Tax | $66.52M | $65.25M | $189.12M | $181.15M | $118.48M | $107.75M | $230.84M | $199.44M | $240.24M | $154.64M | $47.12M | $31.14M | $24.44M | $-33.19M | $-26.66M | $28.88M | $-9.13M | $57.11M | $199.67M | $165.34M |
| Income Before Tax Ratio | 15.63% | 13.31% | 34.01% | 31.32% | 28.55% | 28.57% | 45.02% | 40.10% | 45.32% | 40.46% | 15.68% | 14.32% | 11.44% | -19.32% | -15.68% | 14.89% | -5.22% | 23.08% | 51.58% | 40.15% |
| Income Tax Expense | $214.00K | $4.80M | $1.54M | $1.55M | $226.00K | $4.00K | $161.00K | $-186.00K | $202.00K | $204.00K | $19.00K | $-13.00K | $4.66M | $15.00K | $-25.00K | $-14.00K | $47.00K | $-14.00K | $-55.00K | $8.00K |
| Net Income | $66.73M | $60.46M | $187.57M | $180.82M | $118.37M | $107.74M | $230.67M | $199.63M | $242.85M | $154.44M | $47.10M | $31.15M | $19.78M | $-33.21M | $-26.63M | $28.89M | $-9.19M | $57.07M | $199.66M | $165.33M |
| Net Income Ratio | 15.68% | 12.33% | 33.73% | 31.26% | 28.52% | 28.57% | 44.99% | 40.14% | 45.81% | 40.41% | 15.68% | 14.32% | 9.26% | -19.33% | -15.66% | 14.90% | -5.25% | 23.07% | 51.58% | 40.15% |
| EPS | $0.30 | $0.27 | $0.84 | $0.81 | $0.53 | $0.48 | $1.04 | $0.90 | $1.08 | $0.69 | $0.23 | $0.15 | $0.10 | $-0.17 | $-0.13 | $0.15 | $-0.05 | $0.29 | $1.01 | $0.87 |
| EPS Diluted | $0.30 | $0.27 | $0.84 | $0.81 | $0.53 | $0.48 | $1.04 | $0.90 | $1.08 | $0.69 | $0.23 | $0.15 | $0.10 | $-0.17 | $-0.13 | $0.15 | $-0.05 | $0.29 | $1.01 | $0.84 |
| Weighted Average Shares Outstanding | 222.62M | 222.62M | 222.62M | 222.62M | 222.62M | 222.62M | 222.62M | 222.62M | 222.25M | 222.62M | 204.77M | 203.53M | 197.83M | 195.33M | 197.69M | 197.69M | 197.69M | 196.79M | 197.68M | 189.43M |
| Weighted Average Shares Outstanding Diluted | 222.62M | 222.62M | 222.62M | 222.62M | 222.62M | 222.62M | 222.62M | 222.62M | 222.25M | 223.82M | 204.77M | 203.53M | 197.83M | 195.33M | 204.85M | 197.78M | 197.69M | 196.79M | 197.68M | 197.76M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $413.53M | $308.32M | $254.53M | $113.07M | $174.72M |
| Short Term Investments | $4.03M | $7.43M | $236.28M | $2.44M | $2.64M |
| Cash and Short Term Investments | $417.56M | $315.75M | $490.81M | $115.51M | $177.36M |
| Net Receivables | $- | $143.94M | $237.15M | $83.94M | $84.90M |
| Inventory | $- | $245.22M | $80.79M | $119.28M | $92.56M |
| Other Current Assets | $408.45M | $23.01M | $45.98M | $14.01M | $23.49M |
| Total Current Assets | $826.01M | $727.93M | $881.05M | $332.75M | $378.32M |
| Property Plant Equipment Net | $5.25B | $4.64B | $3.71B | $3.66B | $3.42B |
| Goodwill | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M |
| Long Term Investments | $11.79M | $51.50M | $16.30M | $555.00K | $1.28M |
| Tax Assets | $- | $- | $- | $1.39M | $1.39M |
| Other Non-Current Assets | $22.42M | $355.48M | $56.89M | $12.73M | $7.20M |
| Total Non-Current Assets | $5.39B | $5.15B | $3.90B | $3.78B | $3.54B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $6.22B | $5.88B | $4.78B | $4.12B | $3.92B |
| Account Payables | $- | $7.80M | $7.99M | $2.33M | $7.86M |
| Short Term Debt | $461.47M | $263.10M | $278.88M | $207.39M | $179.44M |
| Tax Payables | $- | $- | $- | $315.00K | $669.00K |
| Deferred Revenue | $- | $- | $- | $3.12M | $5.69M |
| Other Current Liabilities | $134.18M | $138.15M | $104.79M | $114.87M | $93.39M |
| Total Current Liabilities | $595.65M | $409.05M | $391.66M | $292.68M | $281.36M |
| Long Term Debt | $3.28B | $3.20B | $2.11B | $2.18B | $2.02B |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $452.00K | $472.00K | $2.05M | $-4.68M | $3.74M |
| Total Non-Current Liabilities | $3.28B | $3.20B | $2.12B | $2.17B | $2.03B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $3.88B | $3.61B | $2.51B | $2.46B | $2.31B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $222.62M | $222.62M | $222.62M | $203.53M | $197.69M |
| Retained Earnings | $507.47M | $446.00M | $436.19M | $-3.13M | $8.02M |
| Accumulated Other Comprehensive Income Loss | $1.78M | $415.00K | $454.00K | $228.00K | $200.00K |
| Other Total Stockholders Equity | $1.61B | $1.61B | $1.61B | $1.45B | $1.41B |
| Total Stockholders Equity | $2.34B | $2.28B | $2.27B | $1.65B | $1.61B |
| Total Equity | $2.34B | $2.28B | $2.27B | $1.65B | $1.61B |
| Total Liabilities and Stockholders Equity | $6.22B | $5.88B | $4.78B | $4.12B | $3.92B |
| Minority Interest | $-472.00K | $-472.00K | $-472.00K | $-472.00K | $-472.00K |
| Total Liabilities and Total Equity | $6.22B | $5.88B | $4.78B | $4.12B | $3.92B |
| Total Investments | $15.81M | $58.94M | $252.58M | $2.99M | $3.92M |
| Total Debt | $3.75B | $3.46B | $2.37B | $2.37B | $2.20B |
| Net Debt | $3.33B | $3.15B | $2.12B | $2.26B | $2.03B |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $413.53M | $320.88M | $359.24M | $297.35M | $308.32M | $285.38M | $306.82M | $225.36M | $254.53M | $127.36M | $119.81M | $111.18M | $113.07M | $122.06M | $140.36M | $151.01M | $174.72M | $194.11M | $224.72M | $218.54M |
| Short Term Investments | $4.03M | $5.43M | $8.25M | $6.16M | $7.43M | $230.20M | $212.31M | $233.11M | $236.28M | $213.26M | $166.19M | $2.70M | $2.44M | $2.89M | $2.67M | $3.12M | $2.64M | $1.75M | $1.53M | $3.94M |
| Cash and Short Term Investments | $417.56M | $326.31M | $367.48M | $303.51M | $315.75M | $515.58M | $519.14M | $458.47M | $490.81M | $340.61M | $286.00M | $113.88M | $115.51M | $124.95M | $143.03M | $154.13M | $177.36M | $195.86M | $226.25M | $222.49M |
| Net Receivables | $- | $- | $174.72M | $- | $143.94M | $- | $252.49M | $- | $237.15M | $- | $- | $118.99M | $85.21M | $- | $76.35M | $102.76M | $84.90M | $88.37M | $106.18M | $114.58M |
| Inventory | $- | $- | $286.40M | $- | $245.22M | $156.40M | $211.43M | $- | $217.75M | $- | $125.20M | $135.96M | $119.28M | $115.64M | $100.19M | $66.26M | $92.56M | $97.60M | $112.51M | $144.07M |
| Other Current Assets | $408.45M | $455.93M | $30.67M | $536.20M | $23.01M | $340.23M | $27.40M | $375.00M | $45.98M | $352.50M | $287.85M | $33.99M | $5.11M | $195.54M | $38.68M | $51.45M | $23.49M | $208.57M | $242.22M | $277.11M |
| Total Current Assets | $826.01M | $782.25M | $859.27M | $839.71M | $727.93M | $855.80M | $897.58M | $833.47M | $881.05M | $693.12M | $573.85M | $355.73M | $332.75M | $320.49M | $331.65M | $374.60M | $378.32M | $404.42M | $468.48M | $499.60M |
| Property Plant Equipment Net | $5.25B | $5.36B | $5.44B | $5.62B | $4.64B | $3.57B | $3.63B | $3.71B | $3.71B | $3.67B | $3.63B | $3.56B | $3.66B | $3.52B | $3.53B | $3.42B | $3.42B | $3.44B | $3.45B | $3.36B |
| Goodwill | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M | $112.45M |
| Long Term Investments | $11.79M | $11.51M | $42.26M | $13.60M | $51.50M | $12.27M | $13.96M | $12.74M | $16.30M | $13.67M | $6.51M | $463.00K | $555.00K | $555.00K | $555.00K | $1.34M | $1.28M | $2.90M | $4.16M | $17.65M |
| Tax Assets | $- | $- | $- | $- | $-1 | $- | $- | $- | $- | $- | $- | $- | $- | $25.24M | $5.95M | $1.39M | $1.39M | $1.39M | $1.50M | $1.50M |
| Other Non-Current Assets | $22.42M | $21.59M | $- | $35.66M | $355.48M | $52.71M | $52.71M | $48.75M | $56.89M | $58.95M | $44.14M | $32.52M | $14.12M | $5.59M | $5.06M | $15.25M | $7.20M | $19.28M | $14.70M | $11.46M |
| Total Non-Current Assets | $5.39B | $5.50B | $5.59B | $5.78B | $5.15B | $3.74B | $3.80B | $3.89B | $3.90B | $3.86B | $3.79B | $3.71B | $3.78B | $3.67B | $3.65B | $3.55B | $3.54B | $3.58B | $3.58B | $3.50B |
| Other Assets | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $6.22B | $6.28B | $6.45B | $6.62B | $5.88B | $4.60B | $4.70B | $4.72B | $4.78B | $4.55B | $4.37B | $4.06B | $4.12B | $3.99B | $3.98B | $3.93B | $3.92B | $3.98B | $4.05B | $4.00B |
| Account Payables | $- | $- | $111.13M | $- | $7.80M | $64.21M | $63.40M | $- | $7.99M | $- | $11.89M | $8.66M | $2.33M | $4.92M | $5.63M | $6.60M | $7.86M | $9.61M | $10.48M | $28.33M |
| Short Term Debt | $461.47M | $403.30M | $456.17M | $325.65M | $263.10M | $366.12M | $363.62M | $366.29M | $278.88M | $258.03M | $417.98M | $443.72M | $207.39M | $175.31M | $334.96M | $181.38M | $179.44M | $236.34M | $550.13M | $504.52M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $315.00K | $- | $- | $- | $669.00K | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $-64.21M | $-63.40M | $- | $- | $- | $-11.89M | $- | $3.12M | $69.77M | $66.21M | $-6.60M | $5.69M | $80.72M | $62.28M | $77.89M |
| Other Current Liabilities | $134.18M | $144.38M | $54.51M | $153.46M | $138.15M | $46.61M | $40.55M | $108.68M | $104.79M | $166.58M | $112.97M | $85.75M | $126.22M | $87.23M | $86.08M | $85.27M | $93.39M | $117.45M | $105.73M | $107.42M |
| Total Current Liabilities | $595.65M | $547.68M | $621.81M | $479.11M | $409.05M | $476.94M | $467.57M | $474.96M | $391.66M | $424.61M | $542.84M | $538.13M | $292.68M | $267.47M | $426.68M | $273.26M | $281.36M | $363.39M | $666.34M | $640.27M |
| Long Term Debt | $3.28B | $3.39B | $3.40B | $3.77B | $3.20B | $1.89B | $1.93B | $2.02B | $2.11B | $2.10B | $1.91B | $1.84B | $2.18B | $2.14B | $1.94B | $2.01B | $2.02B | $1.99B | $1.71B | $1.74B |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $452.00K | $466.00K | $463.00K | $460.00K | $472.00K | $5.38M | $3.36M | $3.32M | $2.05M | $1.45M | $1.40M | $1.24M | $-4.68M | $915.00K | $1.24M | $2.50M | $3.74M | $5.08M | $6.33M | $8.57M |
| Total Non-Current Liabilities | $3.28B | $3.39B | $3.40B | $3.77B | $3.20B | $1.90B | $1.94B | $2.02B | $2.12B | $2.10B | $1.92B | $1.84B | $2.17B | $2.14B | $1.94B | $2.01B | $2.03B | $2.00B | $1.72B | $1.75B |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $3.88B | $3.94B | $4.03B | $4.25B | $3.61B | $2.37B | $2.41B | $2.50B | $2.51B | $2.52B | $2.46B | $2.38B | $2.46B | $2.41B | $2.37B | $2.29B | $2.31B | $2.36B | $2.39B | $2.39B |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $222.62M | $222.62M | $222.62M | $222.62M | $222.62M | $222.62M | $222.62M | $222.62M | $222.62M | $222.62M | $203.53M | $203.53M | $203.53M | $198.03M | $197.69M | $197.69M | $197.69M | $197.69M | $197.69M | $197.69M |
| Retained Earnings | $507.47M | $516.43M | $594.00M | $1.55B | $446.00M | $394.42M | $464.77M | $389.93M | $436.19M | $196.16M | $75.11M | $28.02M | $-3.13M | $-22.92M | $10.28M | $36.91M | $8.02M | $17.20M | $61.41M | $- |
| Accumulated Other Comprehensive Income Loss | $1.78M | $610.00K | $861.00K | $1.07M | $1.00B | $533.00K | $585.00K | $507.00K | $454.00K | $496.00K | $424.00K | $227.00K | $228.00K | $150.00K | $174.00K | $1.00B | $200.00K | $285.00K | $294.00K | $331.00K |
| Other Total Stockholders Equity | $1.61B | $1.61B | $1.61B | $604.69M | $1.61B | $1.61B | $1.61B | $1.61B | $2.04B | $1.61B | $1.63B | $1.45B | $1.45B | $1.41B | $1.41B | $1.41B | $1.41B | $1.41B | $1.41B | $1.41B |
| Total Stockholders Equity | $2.34B | $2.35B | $2.43B | $2.38B | $2.28B | $2.23B | $2.30B | $2.22B | $2.27B | $2.03B | $1.91B | $1.68B | $1.65B | $1.58B | $1.61B | $1.64B | $1.61B | $1.62B | $1.67B | $1.60B |
| Total Equity | $2.34B | $2.35B | $2.43B | $2.38B | $2.28B | $2.23B | $2.30B | $2.22B | $2.27B | $2.03B | $1.91B | $1.68B | $1.65B | $1.58B | $1.61B | $1.64B | $1.61B | $1.62B | $1.67B | $1.60B |
| Total Liabilities and Stockholders Equity | $6.22B | $6.28B | $6.45B | $6.62B | $5.88B | $4.60B | $4.70B | $4.72B | $4.78B | $4.55B | $4.37B | $4.06B | $4.12B | $3.99B | $3.98B | $3.93B | $3.92B | $3.98B | $4.05B | $4.00B |
| Minority Interest | $-472.00K | $-472.00K | $-472.00K | $-472.00K | $-472.00K | $-472.00K | $-472.00K | $-472.00K | $-472.00K | $-472.00K | $-472.00K | $-472.00K | $-472.00K | $-472.00K | $-472.00K | $-472.00K | $-472.00K | $353.00K | $295.00K | $232.00K |
| Total Liabilities and Total Equity | $6.22B | $6.28B | $6.45B | $6.62B | $5.88B | $4.60B | $4.70B | $4.72B | $4.78B | $4.55B | $4.37B | $4.06B | $4.12B | $3.99B | $3.98B | $3.93B | $3.92B | $3.98B | $4.05B | $4.00B |
| Total Investments | $15.81M | $16.94M | $19.71M | $19.76M | $58.94M | $242.47M | $226.27M | $245.85M | $252.58M | $226.93M | $172.70M | $3.17M | $2.99M | $3.45M | $3.23M | $4.46M | $3.92M | $4.64M | $5.70M | $21.59M |
| Total Debt | $3.75B | $3.79B | $3.86B | $4.09B | $3.46B | $2.26B | $2.30B | $2.39B | $2.37B | $2.35B | $2.33B | $2.28B | $2.37B | $2.31B | $2.28B | $2.19B | $2.20B | $2.23B | $2.26B | $2.25B |
| Net Debt | $3.33B | $3.47B | $3.50B | $3.80B | $3.15B | $1.97B | $1.99B | $2.16B | $2.12B | $2.23B | $2.21B | $2.17B | $2.26B | $2.19B | $2.13B | $2.04B | $2.03B | $2.04B | $2.04B | $2.03B |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $495.58M | $656.41M | $472.72M | $-11.15M | $413.01M |
| Depreciation and Amortization | $339.03M | $230.94M | $156.20M | $152.98M | $144.39M |
| Deferred Income Tax | $- | $- | $-4.70M | $-185.00K | $- |
| Stock Based Compensation | $- | $10.72M | $4.70M | $185.00K | $- |
| Change in Working Capital | $- | $-8.51M | $-132.00M | $-35.41M | $44.91M |
| Accounts Receivables | $- | $14.82M | $-59.58M | $-22.45M | $21.99M |
| Inventory | $- | $-27.67M | $-98.56M | $-26.72M | $43.85M |
| Accounts Payables | $- | $10.47M | $5.67M | $-5.53M | $-3.84M |
| Other Working Capital | $- | $-6.13M | $20.47M | $19.29M | $-17.09M |
| Other Non Cash Items | $-98.20M | $-33.38M | $-126.03M | $-43.49M | $1.75M |
| Net Cash Provided by Operating Activities | $736.41M | $856.18M | $370.89M | $62.93M | $604.06M |
| Investments in Property Plant and Equipment | $-915.25M | $-1.63B | $-317.96M | $-462.40M | $-724.32M |
| Acquisitions Net | $- | $142.74M | $-1.50M | $5.62M | $-14.89M |
| Purchases of Investments | $- | $- | $-1.50M | $-357.00K | $-750.00K |
| Sales Maturities of Investments | $- | $251.84M | $1.50M | $14.07M | $750.00K |
| Other Investing Activities | $431.85M | $1.39M | $80.00M | $80.00M | $23.24M |
| Net Cash Used for Investing Activities | $-483.40M | $-1.24B | $-239.47M | $-363.06M | $-715.97M |
| Debt Repayment | $286.31M | $1.07B | $46.84M | $175.06M | $444.03M |
| Common Stock Issued | $- | $- | $- | $52.45M | $5.83M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $-434.12M | $-638.93M | $-33.39M | $- | $-312.39M |
| Other Financing Activities | $- | $-862.00K | $- | $52.45M | $-7.46M |
| Net Cash Used Provided by Financing Activities | $-147.80M | $433.07M | $10.03M | $223.55M | $124.18M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $105.21M | $53.80M | $141.45M | $-76.58M | $12.27M |
| Cash at End of Period | $413.53M | $308.32M | $254.53M | $113.07M | $189.65M |
| Cash at Beginning of Period | $308.32M | $254.53M | $113.07M | $189.65M | $177.38M |
| Operating Cash Flow | $736.41M | $856.18M | $370.89M | $62.93M | $604.06M |
| Capital Expenditure | $-915.25M | $-1.63B | $-317.96M | $-462.40M | $-724.32M |
| Free Cash Flow | $-178.84M | $-775.24M | $52.93M | $-399.47M | $-120.26M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $66.73M | $60.46M | $187.57M | $180.82M | $118.37M | $156.24M | $230.67M | $199.63M | $240.03M | $154.44M | $47.10M | $31.15M | $19.78M | $-33.21M | $-26.63M | $28.89M | $-9.18M | $57.13M | $199.72M | $165.33M |
| Depreciation and Amortization | $83.15M | $84.16M | $83.71M | $88.01M | $60.02M | $41.51M | $57.10M | $55.55M | $40.49M | $39.23M | $37.51M | $38.97M | $40.05M | $38.57M | $37.42M | $36.94M | $37.51M | $37.28M | $35.33M | $34.27M |
| Deferred Income Tax | $- | $- | $- | $- | $- | $- | $- | $- | $-4.70M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $- | $- | $- | $- | $11.25M | $- | $- | $- | $4.70M | $- | $- | $- | $185.00K | $- | $- | $- | $- | $- | $- | $- |
| Change in Working Capital | $- | $10.99M | $12.39M | $-66.97M | $-49.54M | $-60.97M | $-8.03M | $7.12M | $-39.65M | $-56.65M | $-15.74M | $-19.08M | $-21.34M | $-4.15M | $21.73M | $-31.63M | $7.96M | $39.95M | $8.09M | $-11.09M |
| Accounts Receivables | $- | $- | $- | $- | $10.85M | $- | $- | $- | $-131.73M | $- | $- | $- | $-26.24M | $- | $- | $- | $58.62M | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $-28.25M | $- | $- | $- | $-26.41M | $- | $- | $- | $-22.93M | $- | $- | $- | $7.22M | $- | $- | $- |
| Accounts Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Working Capital | $- | $10.99M | $12.39M | $-66.97M | $-49.00M | $-60.97M | $-8.03M | $7.12M | $118.48M | $-56.65M | $-15.74M | $-19.19M | $46.70M | $-4.15M | $21.73M | $-31.63M | $-54.05M | $39.95M | $8.09M | $-11.09M |
| Other Non Cash Items | $17.97M | $8.95M | $-51.00M | $145.50M | $91.69M | $-65.34M | $3.40M | $428.00K | $-21.12M | $-68.38M | $-3.70M | $-33.70M | $-13.26M | $-4.73M | $-3.30M | $-22.20M | $-9.83M | $-2.27M | $-2.35M | $16.20M |
| Net Cash Provided by Operating Activities | $167.85M | $164.55M | $232.68M | $171.33M | $100.50M | $71.44M | $283.14M | $262.72M | $219.75M | $68.64M | $65.17M | $17.34M | $25.24M | $-3.52M | $29.22M | $12.00M | $26.46M | $132.09M | $240.79M | $204.72M |
| Investments in Property Plant and Equipment | $-4.32M | $-2.43M | $-9.43M | $-899.06M | $-1.48B | $-84.33M | $-2.57M | $-150.71M | $-79.25M | $-79.08M | $-148.45M | $-11.19M | $-225.57M | $-36.85M | $-137.65M | $-44.33M | $-8.68M | $-30.86M | $-125.65M | $-560.95M |
| Acquisitions Net | $- | $- | $- | $174.00M | $- | $-1.50M | $43.61M | $8.69M | $- | $-1.50M | $- | $80.00M | $2.81M | $- | $- | $2.81M | $-14.14M | $- | $- | $-750.00K |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $-36.31M | $-8.69M | $- | $-1.50M | $- | $- | $357.00K | $- | $-357.00K | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $251.84M | $- | $-7.30M | $8.69M | $- | $3.01M | $- | $- | $- | $- | $14.07M | $- | $- | $- | $- | $- |
| Other Investing Activities | $49.50M | $- | $208.35M | $174.00M | $251.84M | $- | $43.61M | $99.13M | $- | $-1.50M | $- | $80.00M | $80.00M | $-18.00M | $13.72M | $2.81M | $533.75M | $- | $26.56M | $-1.50M |
| Net Cash Used for Investing Activities | $45.18M | $-2.43M | $198.92M | $-725.06M | $-1.23B | $-85.83M | $41.04M | $-42.90M | $-79.25M | $-80.58M | $-148.45M | $68.81M | $-142.76M | $-54.85M | $-123.93M | $-41.52M | $-22.82M | $-30.86M | $-99.09M | $-563.20M |
| Debt Repayment | $-44.69M | $-62.44M | $-231.45M | $625.12M | $1.22B | $-45.64M | $-86.89M | $-10.78M | $19.60M | $21.94M | $92.71M | $-88.11M | $61.70M | $39.25M | $83.47M | $-5.26M | $-19.90M | $-28.62M | $7.51M | $488.23M |
| Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $51.76M | $684.00K | $- | $- | $- | $- | $- | $5.83M |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $-75.69M | $-138.03M | $-138.03M | $-82.37M | $-66.79M | $-178.10M | $-155.84M | $-238.21M | $-33.39M | $-178.10M | $- | $- | $- | $- | $- | $- | $- | $-97.36M | $-138.25M | $-76.78M |
| Other Financing Activities | $1 | $- | $-233.00K | $- | $-231.00K | $- | $- | $- | $463.00K | $175.65M | $- | $57.00K | $46.84M | $-1.01M | $-1.04M | $-1.08M | $-4.72M | $-5.68M | $-1.18M | $-4.89M |
| Net Cash Used Provided by Financing Activities | $-120.38M | $-200.47M | $-369.71M | $542.75M | $1.15B | $21.94M | $-242.72M | $-248.98M | $-13.33M | $19.49M | $91.92M | $-88.05M | $108.54M | $38.93M | $82.43M | $-6.34M | $-24.62M | $-131.66M | $-131.92M | $412.38M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $92.65M | $-38.35M | $61.88M | $-10.97M | $22.94M | $7.54M | $81.46M | $-29.16M | $127.17M | $7.54M | $8.64M | $-1.90M | $-8.98M | $-19.45M | $-12.29M | $-35.86M | $-20.98M | $-30.43M | $9.78M | $53.90M |
| Cash at End of Period | $413.53M | $320.88M | $359.24M | $297.35M | $308.32M | $127.36M | $306.82M | $225.36M | $254.53M | $127.36M | $119.81M | $111.18M | $113.07M | $122.06M | $141.50M | $153.79M | $189.65M | $210.63M | $241.06M | $231.28M |
| Cash at Beginning of Period | $320.88M | $359.24M | $297.35M | $308.32M | $285.38M | $119.81M | $225.36M | $254.53M | $127.36M | $119.81M | $111.17M | $113.07M | $122.06M | $141.50M | $153.79M | $189.65M | $210.63M | $241.06M | $231.28M | $177.38M |
| Operating Cash Flow | $167.85M | $164.55M | $232.68M | $171.33M | $100.50M | $71.44M | $283.14M | $262.72M | $219.75M | $68.64M | $65.17M | $17.34M | $25.24M | $-3.52M | $29.22M | $12.00M | $26.46M | $132.09M | $240.79M | $204.72M |
| Capital Expenditure | $-4.32M | $-2.43M | $-9.43M | $-899.06M | $-1.48B | $-84.33M | $-2.57M | $-150.71M | $-79.25M | $-79.08M | $-148.45M | $-11.19M | $-225.57M | $-36.85M | $-137.65M | $-44.33M | $-8.68M | $-30.86M | $-125.65M | $-560.95M |
| Free Cash Flow | $163.53M | $162.12M | $223.24M | $-727.73M | $-1.38B | $-12.89M | $280.57M | $112.00M | $140.50M | $-10.44M | $-83.28M | $6.15M | $-200.33M | $-40.38M | $-108.43M | $-32.33M | $17.78M | $101.23M | $115.14M | $-356.23M |
Frontline Dividends
Explore Frontline's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
13.74%
Dividend Payout Ratio
87.60%
Dividend Paid & Capex Coverage Ratio
0.55x
Frontline Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.2 | $0.2 | March 14, 2025 | March 14, 2025 | March 31, 2025 | February 28, 2025 |
| $0.34 | $0.34 | December 11, 2024 | December 11, 2024 | December 31, 2024 | November 27, 2024 |
| $0.62 | $0.62 | September 13, 2024 | September 13, 2024 | September 30, 2024 | August 30, 2024 |
| $0.62 | $0.62 | June 14, 2024 | June 14, 2024 | June 28, 2024 | May 29, 2024 |
| $0.37 | $0.37 | March 14, 2024 | March 15, 2024 | March 27, 2024 | February 28, 2024 |
| $0.3 | $0.3 | December 14, 2023 | December 15, 2023 | December 29, 2023 | November 29, 2023 |
| $0.8 | $0.8 | September 14, 2023 | September 15, 2023 | September 29, 2023 | August 23, 2023 |
| $0.7 | $0.7 | June 15, 2023 | June 16, 2023 | June 30, 2023 | May 31, 2023 |
| $1.07 | $1.07 | March 15, 2023 | March 16, 2023 | March 31, 2023 | February 28, 2023 |
| $0.15 | $0.15 | September 15, 2022 | September 16, 2022 | October 03, 2022 | August 25, 2022 |
| $0.5 | $0.5 | September 10, 2020 | September 11, 2020 | September 29, 2020 | August 26, 2020 |
| $0.7 | $0.7 | June 03, 2020 | June 04, 2020 | June 22, 2020 | May 20, 2020 |
| $0.4 | $0.4 | March 12, 2020 | March 13, 2020 | March 26, 2020 | February 27, 2020 |
| $0.1 | $0.1 | December 10, 2019 | December 11, 2019 | December 20, 2019 | November 26, 2019 |
| $0.15 | $0.15 | June 08, 2017 | June 12, 2017 | June 21, 2017 | May 30, 2017 |
| $0.15 | $0.15 | March 09, 2017 | March 13, 2017 | March 23, 2017 | March 01, 2017 |
| $0.1 | $0.1 | December 13, 2016 | December 15, 2016 | December 22, 2016 | November 30, 2016 |
| $0.2 | $0.2 | September 08, 2016 | September 12, 2016 | September 19, 2016 | August 31, 2016 |
| $0.4 | $0.4 | June 09, 2016 | June 13, 2016 | June 20, 2016 | June 01, 2016 |
| $0.35 | $0.35 | March 09, 2016 | March 11, 2016 | March 18, 2016 | March 01, 2016 |
Frontline News
Read the latest news about Frontline, including recent articles, headlines, and updates.
Are Investors Undervaluing FRONTLINE PLC (FRO) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML
Represents first ever triplet combination using targeted radiotherapy as a backbone therapy in AML with initial clinical data expected in 2H:2025 Expansion into frontline setting greatly expands potential addressable patient opportunity for Actimab-A Triplet combination supported by previously completed Phase 1 trials of Actimab-A + Venetoclax and Actimab-A + CLAG-M demonstrating Actimab-A's mutation agnostic and synergistic potential NEW YORK , March 11, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that the first clinical trial under its previously announced Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for Actimab-A has been initiated. The trial (NCT06802523) will evaluate the triplet combination comprised of Actimab-A, Venetoclax (Abbvie/Roche) an oral Bcl-2 inhibitor and ASTX-727 (Taiho Oncology, an Otsuka holdings company) a novel oral hypomethylating agent (HMA) in frontline acute myeloid leukemia (AML) patients.
Win-Win Momentum Plays With Strong Dividend Yields
Whether deserved or not, dividend stocks have a reputation for being somewhat boring—sturdy and dependable, but in low-growth industries or comprising companies that are well beyond their days of rapid share price gains. Though dividend stocks are not necessarily safe in all cases, they have a reputation for being a strong defensive play.
Frontline Plc (FRO) Q4 2024 Earnings Call Transcript
Frontline Plc (NYSE:FRO ) Q4 2024 Earnings Conference Call February 28, 2025 9:00 AM ET Company Participants Lars Barstad - Chief Executive Officer Inger Klemp - Chief Financial Officer Conference Call Participants Jonathan Chappell - Evercore ISI Omar Nokta - Jefferies Sherif Elmaghrabi - BTIG Lars Barstad Thank you very much, dear all, and thank you for dialing into Frontline's quarterly earnings call. Being in the tanker industry, one is used to evolving and ever changing markets, largely affected by geopolitical events, but it's becoming a little bit exhausting having potential seismic shifts by the hour.
Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort
Aptose Announces Positive Clinical Safety Review and Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib
10 Ideal 'Safer' January Dividend Buys, Out Of 40 Choices From Readers
Before January 31, 2025, my REaders mentioned 40 equities in their comments on my articles. Some bad-news investments (ROgues) mixed with (mostly) FAvorites. Thus, readers spoke-up about the ReFa/Ro. Ten analyst-target-estimated TOP-NET-GAIN ReFa/Ro: CAG, VZ, DOW, PFE, MRK GOGL, PK, PBR FRO, and TRMD averaged 40.36% net gains from reader data collected 2/17/25. Ten analysts target-augured January TOP-PRICE-UPSIDE reader faves & rogues (ReFa/Ro) were: CAG, VZ, PBR, DOW, PFE, GOGL, TRMD, PK, MRK, & FRO, boasting a 27.91% average target price upside estimate.
Aptose's Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial
TUS+VEN+AZA triplet achieves Cycle 1 complete remission (CR) in TP53-mutated/CK AML TUS+VEN+AZA triplet achieves Cycle 1 complete remissions in FLT3-wildtype AML patients TUS+VEN+AZA triplet shows favorable safety with no alteration of VEN and AZA dosing PK levels of TUS in the triplet remain equivalent to levels as TUS or TUS+VEN therapy SAN DIEGO and TORONTO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company, today reported promising early safety and response results from newly diagnosed acute myeloid leukemia (AML) patients dosed in Aptose's Phase 1/2 TUSCANY trial with a 40 mg dose of tuspetinib in combination with standard of care dosing of venetoclax and azacitidine (TUS+VEN+AZA triplet). The TUS+VEN+AZA triplet is being developed as a frontline therapy to treat large, mutationally diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy.
Verizon Frontline delivering 5G connectivity to New York State Police cruisers
ALBANY, N.Y., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Verizon Frontline today announced it will provide 5G connectivity across the New York State Police's fleet of vehicles through the activation of more than 1,800 lines of service.
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
SAN DIEGO and TORONTO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company, today announced dosing the first set of patients in the TUSCANY Phase 1/2 study with tuspetinib (TUS) in combination with venetoclax (VEN) and azacitidine (AZA) as a frontline triple drug combination (triplet) therapy for patients newly diagnosed with acute myeloid leukemia, or AML. Tuspetinib based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 trial with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active across diverse AML populations, durable, and well tolerated.
New Body Camera by Motorola Solutions Boosts Safety for Frontline Workers
CHICAGO--(BUSINESS WIRE)--Motorola Solutions (NYSE: MSI) today unveiled the V200, a body camera designed specifically to help protect frontline workers in stores, hospitals, hotels, schools and stadiums. Workers in these settings regularly face safety concerns – from unwelcome behavior to theft and medical emergencies – and the V200, with its GoLive Audio safety feature, offers a direct connection to help. The V200 body camera is a discreet, lightweight addition to a worker's uniform. The recor.
4 Of 35 Safe-Buy Dividend Power Dogs In January
Four low-priced Dividend Power stocks, Golden Ocean, Invesco Mortgage, ARMOUR Residential, and FutureFuel, offer safer dividends with free cash-flow yields exceeding dividend yields. The Dividend Power strategy focuses on high earnings yield and top dividend yield stocks, creating a resilient portfolio for both downturns and bull markets. Analysts project significant gains for top Dividend Power stocks, with an average net gain of 79.97% on $10k invested in the top ten.
Verizon Frontline powers NORAD Tracks Santa initiative for 22nd year
Enhanced network solutions and Verizon Frontline assets provide redundancy and reliability so children around the world can track Santa Enhanced network solutions and Verizon Frontline assets provide redundancy and reliability so children around the world can track Santa
Verizon Frontline Crisis Response Team supports 800+ agencies during 2024 emergency responses
What you need to know: The Verizon Frontline Crisis Response Team deployed nearly 900 times in 2024, supporting first responders in nearly every state and Washington D.C. The team responded to requests for support from public safety agencies during responses to tornadoes, hurricanes, and wildfires.
100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial
Two of three patients achieved both complete remission and MRD-negative status High response rates observed in earlier studies continue in ongoing mipletamig trial Cohort 2 enrollment commencing SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel bispecific immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced 100% of patients achieved remission* within 30 days, in Cohort 1 of the RAINIER frontline acute myeloid leukemia (AML) Phase 1b trial, including two patients who experienced complete remission with minimal residual disease (MRD)-negative status (100% elimination of cancer cells). The results build on data from the prior trial, in which 100% of frontline patients also achieved remission.
Spectral AI Incorporates Frontline Feedback into Improved Software Release for Enhanced Diagnostic Precision
DALLAS, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on revolutionizing medical diagnostics to enable faster, more accurate treatment decisions in wound care, today announced the completion of enhancements to its technical file to support significant software updates for its DeepView SnapShot® M and DeepView AI-Burn® system in the UK. These upgrades, informed by real-world experience and frontline feedback from clinicians, are designed to enhance product performance and usability in the UK, further solidifying the Company's commitment to delivering and commercializing cutting-edge solutions in critical care settings.
Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial
– Subgroup analyses from Ph 2 protocol-defined R/R mNPM1 AML efficacy population (N=64) show responses across all major subgroups, including heavily pretreated patients – – 26% CR+CRh (20/77) and 48% ORR (37/77) in all enrolled patients who met the efficacy evaluable criteria in Ph 2 R/R mNPM1 AML cohort – – 100% ORR (37/37) and 95% CRc (35/37) in BEAT AML trial exploring revumenib in combination with venetoclax/azacitidine in newly diagnosed mNPM1 or KMT2Ar AML – – BEAT AML data highlight the potential for revumenib to advance the current standard of care – WALTHAM, Mass. , Dec. 9, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced additional positive data from the AUGMENT-101 trial of Revuforj® (revumenib) in relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML) and the BEAT AML trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed AML patients.
Frontline Stock Drops On Q3 2024 Earnings Report Amidst Tanker Market Uncertainty
Frontline stock hit a 52-week low this week after Q3 2024 earnings. The maritime oil shipping sector is experiencing volatility and uncertainty. Frontline's Q3 earnings were in line and showed YoY growth, but spot contract prices are decreasing.
Verizon Frontline delivers critical connectivity during U.S. Capitol Christmas Tree Harvest
What you need to know: The Verizon Frontline Crisis Response Team supported the U.S. Forest Service with multiple mission-critical communications solutions during the harvest of the U.S. Capitol Christmas Tree near Wrangell, Alaska Advanced communication technologies will assist the crew transporting the tree across the continent from Alaska to Washington, D.C. WRANGELL, Alaska, Nov. 26, 2024 (GLOBE NEWSWIRE) -- The Verizon Frontline Crisis Response Team recently completed a deployment in support of the U.S. Forest Service and other organizations during the harvest of the 2024 U.S. Capitol Christmas Tree.
At 12% Yield, Frontline Is A No-Brainer Investment
Frontline plc offers a high dividend yield of 12%, but has a history of unpredictable dividend cuts, making it suitable for aggressive investors. Despite geopolitical risks, oil prices are expected to stay above $70/barrel, benefiting midstream companies like FRO, which are crucial for oil transport. Earnings estimates for FRO are positive, with expected 25% YoY revenue growth, but the company has a history of disappointing earnings reports.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for FRO.